°øÁö»çÇ×

2023³â ´ëÇѾÏÇÐȸ Çмú»ó ¼ö»óÀÚ
ÀÛ¼ºÀÚ
°ü¸®ÀÚ
ÀÛ¼ºÀÏ
2023-06-20
Á¶È¸
1690
2023³â ´ëÇѾÏÇÐȸ Çмú»ó ¼ö»óÀÚ ¸í´Ü
1. Á¦ 15ȸ ´ëÇѾÏÇÐȸ ¿ì¼ö³í¹®»ó (CRTÀú³Î¿¡ °ÔÀçµÈ ³í¹® Áß ±âÃÊ 2Æí, ÀÓ»ó ¹× Áß°³ 5Æí, »ó±Ý °¢ 200¸¸¿ø)
1) ±âÃʺоß
No.ºÐ¾ßÃ¥ÀÓÀúÀÚ/ 1ÀúÀÚ ³í¹®Á¦¸ñ
1 ±âÃÊ ¼­¿ïÀÇ´ë ¿Àµµ¿¬ Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract Cancer
¼­¿ïÀÇ´ë ¼­Çý¸²
2 ±âÃÊ °¡Å縯ÀÇ´ë ±è¼¼ÁØ Potentiation of the Anticancer Effects by Combining Docetaxel with Ku-0063794 against Triple-Negative Breast Cancer Cells
°¡Å縯ÀÇ´ë Àü¿¹¿ø
2) ÀÓ»ó ¹× Áß°³ ºÐ¾ß
No.ºÐ¾ßÃ¥ÀÓÀúÀÚ/ 1ÀúÀÚ³í¹®Á¦¸ñ
1 ÀÓ»ó ¼­¿ï¾Æ»êº´¿ø Á¤¼®ÈÆ
¼­¿ï¾Æ»êº´¿ø ¼­¼¼¿µ
Functional Impairments in the Mental Health, Depression and Anxiety Related to the Viral Epidemic, and Disruption in Healthcare Service Utilization among Cancer Patients in the COVID-19 Pandemic Era
¼­¿ï¾Æ»êº´¿ø ±è±Ô¹Î
2 ÀÓ»ó ¼­¿ïÀÇ´ë ±èÀÏÇÑ The Role of Postoperative Radiotherapy in Intracranial Solitary Fibrous Tumor/Hemangiopericytoma: A Multi-institutional Retrospective Study (KROG 18-11)
¼­¿ïÀÇ´ë ÀÌÁÖÈ£
3 ÀÓ»ó ¼­¿ï¾Æ»êº´¿ø ¹Ú¼÷·Ã Real-World Efficacy Data and Predictive Clinical Parameters for Treatment Outcomes in Advanced Esophageal Squamous Cell Carcinoma Treated with Immune Checkpoint Inhibitors
°í·ÁÀÇ´ë ±èÁÂÈÆ
4 ÀÓ»ó »ï¼º¼­¿ïº´¿ø ÀÌÀ¯¿µ
»ï¼º¼­¿ïº´¿ø ¹Ú¿ø
Effect of Waiting Time from Pathological Diagnosis to Definitive Concurrent Chemoradiation for Cervical Cancer on Overall Survival
»ï¼º¼­¿ïº´¿ø ³ë°æ¿ø
5 Áß°³ ¿¬¼¼ÀÇ´ë ÀåÁö¼®
¿¬¼¼ÀÇ´ë ¾ÈÁß¹è
Increased Radiosensitivity of Solid Tumors Harboring ATM and BRCA1/2 Mutations
¿¬¼¼ÀÇ´ë ±è°æȯ
¿¬¼¼ÀÇ´ë ±èÇÑ»ó
2. Á¦ 13ȸ ¸ÓÅ© ¾ÏÇмú»ó (CRT¿¡ °ÔÀçµÈ ÀÓ»ó³í¹® Áß ´ëÀå¾Ï, µÎ°æºÎ, Æó¾Ï, ¹æ±¤¾Ï ³í¹®, »ó±Ý °¢ 200¸¸¿ø)
No.Ã¥ÀÓÀúÀÚ/ 1ÀúÀÚ³í¹®Á¦¸ñ
1 ¼­¿ï¾Æ»êº´¿ø ±è¼±¿µ
¼­¿ï¾Æ»êº´¿ø ¼ºÃ¢¿Á
Histopathologic and Molecular Biomarkers of PD-1/PD-L1 Inhibitor Treatment Response among Patients with Microsatellite Instability–High Colon Cancer
¼­¿ï¾Æ»êº´¿ø ÇüÀç¿ø
¾Æ»ê»ý¸í°úÇבּ¸¿ø Á¶ÀºÁ¤
2 ¼­¿ïÀÇ´ë Á¤Ã¢¿í Next-Generation Proteomics–Based Discovery, Verification, and Validation of Urine Biomarkers for Bladder Cancer Diagnosis
¼­¿ïÀÇ´ë ¼­Á¤±³
¼­¿ï´ë »ý¹°ÀÇÇבּ¸¼Ò ÇѵµÇö
3 »ï¼º¼­¿ïº´¿ø ¹Ú¼¼ÈÆ
»ï¼º¼­¿ïº´¿ø Á¤º´Ã¢
Genomic Sequencing for Bladder Urothelial Carcinoma and Its Clinical Implications for Immunotherapy
»ï¼º¼­¿ïº´¿ø ±è·ü
»ï¼º¼­¿ïº´¿ø È«Á¤¿ë
4 ¼­¿ï¾Æ»êº´¿ø ÀÌ´ëÈ£
¼­¿ï¾Æ»êº´¿ø ¹Ú°­¼­
Integrin αvβ3 Induces HSP90 Inhibitor Resistance via FAK Activation in KRAS-Mutant Non–Small Cell Lung Cancer
¼­¿ï¾Æ»êº´¿ø À±½Å±³
5 ¼­¿ïÀÇ´ë ±è¹ü¼® Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: The Concept of Chemo-Selection (KCSG HN13-01)
¼º±Õ°üÀÇ´ë ÀÌÀ±±Ô
°í·ÁÀÇ´ë °­ÀºÁÖ
3. Á¦ 12ȸ ±¤µ¿¾ÏÇмú»ó
1) ÃÖ°í IF SCI ÇмúÁö¿¡ ³í¹®À» ¹ßÇ¥ÇÑ ±âÃÊ ¹× ÀÓ»ó ºÐ¾ßÀÇ Ã¥ÀÓÀúÀÚ °¢ 1¸í
NoºÐ¾ßÃ¥ÀÓÀúÀÚ³í¹®Á¦¸ñ°ÔÀçÇмúÁö
1 ±âÃÊ ¿¬¼¼ÀÇ´ë À̽ÂÅ Analytical and Clinical Validation of Cell-Free Circulating Tumor DNA Assay for the Estimation of Tumor Mutational Burden Clin Chem.
2022;68(12):1519-28
¿¬¼¼ÀÇ´ë ¶ó¼±¿µ
2 ÀÓ»ó ¼­¿ï¾Æ»êº´¿ø Á¤°æÇØ Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer The Neo-PATH Phase 2 Nonrandomized Clinical Trial JAMA Oncol.
2022;8(9):1271-7
»ï¼º¼­¿ïº´¿ø ¹Ú¿¬Èñ
2) ´Ù¼öÀÇ SCI µîÀç ÇмúÁö¿¡ ³í¹®À» ¹ßÇ¥ÇÑ Ã¥ÀÓ ÀúÀÚ 1¸í
NoºÐ¾ßÃ¥ÀÓÀúÀÚ³í¹®Á¦¸ñ°ÔÀçÇмúÁö
1 ´Ù¼ö ¹ßÇ¥ ÇѾçÀÇ´ë ¹Úº¸¿µ Association Between Family History of Gastric Cancer and the Risk of Gastric Cancer and Adenoma: A Nationwide Population-Based Study ¿Ü 7Æí Am J Gastroenterol.
2022;117(8)1255-63
4. Á¦15ȸ ´ëÇѾÏÇÐȸÁö Best Reviewer»ó (4¸í ¼±Á¤, »ó±Ý °¢ 100¸¸¿ø)
: ÃÖ±Ù 2³â°£, 2021³â 1¿ù ~ 2022³â 12¿ù±îÁö ½É»çÇÑ À§¿øÀ¸·Î ½É»ç±â°£À» ÁؼöÇÏ°í, ½É»çÀÇ °´°ü¼º, Ÿ´ç¼º, °Ç¼³ÀûÀÎ ÀÇ°ßÀ¸·Î ³í¹®ÀÇ ÁúÀû Çâ»ó¿¡ ±â¿©ÇÑ ½É»çÀ§¿ø ¼±Á¤
¼ö»óÀÚ
±¸µ¿È¸(¼º±Õ°üÀÇ´ë ³»°ú) ½ÉÈ¿¼·(¿¬¼¼ÀÇ´ë º´¸®°ú)
ÀåÁö¼®(¿¬¼¼ÀÇ´ë ¹æ»ç¼±Á¾¾çÇаú) ÀÌÀº»ó(°í·ÁÀÇ´ë ¼Ò¾ÆÇ÷Á¾³»°ú)